Partner, one of four?1 Nov 2019 13:01
IMO regarding immunotherapy, you have one of four main partners, Roche, Merk, Astra Zeneca or BMS. You combine the drug with a PD1/PDL1 inhibitor and you do a phase1b or phase 3 trial. This will rise on the news of a partner and you don’t need to wait for trial results. Turning a tumour from cold to hot is the main take home for me, increase in PDL1 expression means your checkpoint inhibitor will work better